Elite Pharmaceuticals, Inc. (ELTP)

Market Cap	311.40M -47.0%
Revenue (ttm)	141.01M +33.7%
Net Income	56.67M
EPS	0.04
Shares Out	1.08B
PE Ratio	6.58
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	337,716
Open	0.2995
Previous Close	0.3000
Day's Range	0.2858 - 0.2999
52-Week Range	0.2720 - 0.7400
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 65
• Stock Exchange: OTCMKTS
• Ticker Symbol: ELTP

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 25, 2026

Data Sources Report a data error